4D Molecular Therapeutics FDMT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | -$160.87M-59.5% | -$100.84M+6.2% | -$107.49M-50.7% | ||
| $4.69M+0.9% | $4.65M+10.7% | $4.2M+74.9% | $2.4M+57.8% | ||
| $22.02M-15.7% | $26.12M+32.8% | $19.67M+14.9% | $17.12M+24.1% | ||
| —— | $871K— | —— | —— | ||
| $8.15M— | —— | $3.37M+35.7% | $2.49M+261% | ||
| —— | $3.58M+5,010% | $70K— | —— | ||
| -$209K— | —— | -$734K+76.5% | -$3.13M+79.2% | ||
| $2.93M+42.8% | $2.05M+32.8% | $1.55M+4.6% | $1.48M-1.3% | ||
| -$3.19M-93.4% | -$1.65M-13.6% | -$1.45M-348% | -$324K— | ||
| —— | -$134.59M-77.6% | -$75.79M+12.6% | -$86.69M-25.4% | ||
| —— | $3.79M+36.6% | $2.77M-76.0% | $11.54M+26.6% | ||
| -$92.97M— | —— | $122.4M+818% | -$17.05M+90.1% | ||
| —— | —— | —— | —— | ||
| $112.96M-66.5% | $337.25M+115% | $156.83M+4,903% | $3.14M-97.3% | ||
| —— | -$99.77M— | —— | —— | ||
| $4.73M-34.1% | $7.18M+477% | $1.24M— | —— | ||
| —— | $41K-73.9% | $157K+7,950% | -$2K— | ||
| -$3.19M-93.4% | -$1.65M-13.6% | -$1.45M-348% | -$324K— | ||
| —— | —— | —— | —— | ||
| $2.93M+42.8% | $2.05M+32.8% | $1.55M+4.6% | $1.48M-1.3% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $7.5M— | $0— | —— | —— | ||
| $984K-78.5% | $4.58M— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$209K— | —— | -$734K+76.5% | -$3.13M+79.2% | ||
| -$3.19M-93.4% | -$1.65M-13.6% | -$1.45M-348% | -$324K— | ||
| —— | —— | —— | —— | ||
| $307K— | $0— | —— | —— | ||
| —— | -$138.37M-76.1% | -$78.56M+20.0% | -$98.22M-25.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
